What type of study is this?

September 10, 2025

Demographics and Clinical Outcomes of Carcinoma Rectum Patients After Planned Neoadjuvant Chemoradiotherapy (NACTRT) with Capecitabine-Based Regimen: A 3-Year Experience from a Private Tertiary Cancer Care Centre

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reports survival rates in rectal cancer patients receiving neoadjuvant chemoradiotherapy, indicating significant outcomes.

NACTRT resulted in a pathological complete response (pCR) rate of 22.7% after treatment.
The mean overall survival (OS) for patients was 40 months, showing effective outcomes from the capecitabine regimen.
In total, 79.5% of patients were diagnosed at Stage III, indicating a high incidence of locally advanced rectal cancer.
Challenges included a 47.7% dropout rate for surgery after NACTRT, highlighting barriers to effective treatment.

Nishant Aggarwal (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reports survival rates in rectal cancer patients receiving neoadjuvant chemoradiotherapy, indicating significant outcomes.